KR102720397B1 - 질환 치료용 복소환식 화합물 - Google Patents

질환 치료용 복소환식 화합물 Download PDF

Info

Publication number
KR102720397B1
KR102720397B1 KR1020187016508A KR20187016508A KR102720397B1 KR 102720397 B1 KR102720397 B1 KR 102720397B1 KR 1020187016508 A KR1020187016508 A KR 1020187016508A KR 20187016508 A KR20187016508 A KR 20187016508A KR 102720397 B1 KR102720397 B1 KR 102720397B1
Authority
KR
South Korea
Prior art keywords
optionally substituted
compound
formula
another embodiment
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187016508A
Other languages
English (en)
Korean (ko)
Other versions
KR20180095811A (ko
Inventor
라주 모한
존 누스
제이슨 해리스
Original Assignee
오필란 파마 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오필란 파마 엘티디. filed Critical 오필란 파마 엘티디.
Publication of KR20180095811A publication Critical patent/KR20180095811A/ko
Application granted granted Critical
Publication of KR102720397B1 publication Critical patent/KR102720397B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187016508A 2015-11-13 2016-11-11 질환 치료용 복소환식 화합물 Active KR102720397B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562255041P 2015-11-13 2015-11-13
US62/255,041 2015-11-13
PCT/US2016/061676 WO2017083756A1 (en) 2015-11-13 2016-11-11 Heterocyclic compounds for the treatment of disease

Publications (2)

Publication Number Publication Date
KR20180095811A KR20180095811A (ko) 2018-08-28
KR102720397B1 true KR102720397B1 (ko) 2024-10-21

Family

ID=58696139

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187016508A Active KR102720397B1 (ko) 2015-11-13 2016-11-11 질환 치료용 복소환식 화합물

Country Status (22)

Country Link
US (5) US10683291B2 (enExample)
EP (2) EP4163281B1 (enExample)
JP (3) JP6933384B2 (enExample)
KR (1) KR102720397B1 (enExample)
CN (2) CN114149424B (enExample)
AU (2) AU2016353348A1 (enExample)
BR (1) BR112018009745B1 (enExample)
CA (1) CA3005236C (enExample)
DK (1) DK3373931T3 (enExample)
ES (1) ES2932049T3 (enExample)
HR (1) HRP20221417T1 (enExample)
HU (1) HUE060594T2 (enExample)
IL (1) IL259297B2 (enExample)
LT (1) LT3373931T (enExample)
MX (1) MX382092B (enExample)
PL (1) PL3373931T3 (enExample)
PT (1) PT3373931T (enExample)
RS (1) RS63837B1 (enExample)
RU (1) RU2727194C2 (enExample)
SI (1) SI3373931T1 (enExample)
SM (1) SMT202300062T1 (enExample)
WO (1) WO2017083756A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221417T1 (hr) 2015-11-13 2023-02-03 Oppilan Pharma Ltd. Heterociklički spojevi za liječenje bolesti
WO2018211323A1 (en) * 2017-05-17 2018-11-22 Oppilan Pharma Ltd. Hetercyclic compounds for the treatment of disease
EP3625230A1 (en) * 2017-05-17 2020-03-25 Oppilan Pharma Ltd. Prodrugs for the treatment of disease
GB201815018D0 (en) * 2018-09-14 2018-10-31 Univ Oxford Innovation Ltd Enantiomeric compounds
US12612401B2 (en) 2022-07-06 2026-04-28 Oppilan Pharma Limited Crystalline forms of an S1P receptor modulator
CN120835886A (zh) * 2023-01-13 2025-10-24 奥比兰制药有限公司 S1p受体调节剂的制备

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131336A1 (en) 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
US20070043014A1 (en) 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2010065760A1 (en) * 2008-12-04 2010-06-10 Exelixis, Inc. Imidazo [1,2a] pyridine derivatives, their use as s1p1 agonists and methods for their production
US20130158001A1 (en) 2010-07-20 2013-06-20 Jagabandhu Das Substituted 3-phenyl-1,2,4-oxadiazole compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772597A (en) * 1983-10-14 1988-09-20 Pfizer Inc. 2-azacycloalkylthiopenem derivatives
GB0511684D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
RU2425832C2 (ru) * 2006-04-03 2011-08-10 Астеллас Фарма Инк. Гетеросоединение
US20110207704A1 (en) 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
RU2009127095A (ru) 2006-12-15 2011-01-20 Эбботт Лэборетриз (Us) Новые оксадиазольные соединения
WO2010117662A1 (en) 2009-03-30 2010-10-14 Exelixis, Inc. Modulators of s1p and methods of making and using
US9011494B2 (en) 2009-09-24 2015-04-21 Warsaw Orthopedic, Inc. Composite vertebral rod system and methods of use
HUE036391T2 (hu) 2009-11-13 2018-07-30 Celgene Int Ii Sarl Szfingozin 1 foszfát receptor modulátorok és királis szintézis eljárások
US20140288052A1 (en) 2011-10-20 2014-09-25 GlaxoSmithKline, LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
JP6383418B2 (ja) 2013-11-27 2018-08-29 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
HRP20221417T1 (hr) 2015-11-13 2023-02-03 Oppilan Pharma Ltd. Heterociklički spojevi za liječenje bolesti

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070043014A1 (en) 2003-10-01 2007-02-22 Merck & Co., Inc. 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2006131336A1 (en) 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
WO2010065760A1 (en) * 2008-12-04 2010-06-10 Exelixis, Inc. Imidazo [1,2a] pyridine derivatives, their use as s1p1 agonists and methods for their production
US20100160369A1 (en) 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
US20130158001A1 (en) 2010-07-20 2013-06-20 Jagabandhu Das Substituted 3-phenyl-1,2,4-oxadiazole compounds

Also Published As

Publication number Publication date
HUE060594T2 (hu) 2023-03-28
BR112018009745A2 (pt) 2018-11-06
JP7174963B2 (ja) 2022-11-18
CN114149424B (zh) 2025-05-13
RU2018121416A3 (enExample) 2019-12-17
JP2023017862A (ja) 2023-02-07
KR20180095811A (ko) 2018-08-28
BR112018009745A8 (pt) 2019-02-26
DK3373931T3 (da) 2022-11-28
MX382092B (es) 2025-03-04
AU2021202945A1 (en) 2021-06-03
US20200325135A1 (en) 2020-10-15
SMT202300062T1 (it) 2023-03-17
RU2018121416A (ru) 2019-12-13
US20260092064A1 (en) 2026-04-02
US10683291B2 (en) 2020-06-16
JP7445325B2 (ja) 2024-03-07
WO2017083756A1 (en) 2017-05-18
US20190241556A1 (en) 2019-08-08
HRP20221417T1 (hr) 2023-02-03
IL259297B (en) 2022-11-01
US20220227767A1 (en) 2022-07-21
MX2018005987A (es) 2018-11-29
ES2932049T3 (es) 2023-01-09
JP2021191753A (ja) 2021-12-16
JP6933384B2 (ja) 2021-09-08
JP2018535261A (ja) 2018-11-29
EP3373931B1 (en) 2022-09-28
RU2727194C2 (ru) 2020-07-21
PT3373931T (pt) 2022-12-06
CN108463222B (zh) 2021-10-22
LT3373931T (lt) 2023-03-10
US20230339944A1 (en) 2023-10-26
CA3005236A1 (en) 2017-05-18
SI3373931T1 (sl) 2023-02-28
RS63837B1 (sr) 2023-01-31
EP4163281A1 (en) 2023-04-12
IL259297B2 (en) 2023-03-01
CN114149424A (zh) 2022-03-08
AU2016353348A1 (en) 2018-07-05
CN108463222A (zh) 2018-08-28
EP3373931A4 (en) 2019-04-03
PL3373931T3 (pl) 2023-02-06
EP4163281B1 (en) 2026-07-22
IL259297A (en) 2018-07-31
AU2021202945B2 (en) 2022-06-23
BR112018009745B1 (pt) 2023-09-26
CA3005236C (en) 2024-02-20
EP3373931A1 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
JP7174963B2 (ja) 疾患の処置のための複素環化合物
RU2734760C2 (ru) Противоинфекционные соединения
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
JP2016523923A (ja) Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
WO2012072033A1 (zh) 取代的2，3-二氮杂萘酮化合物及其用途
KR20170117030A (ko) 질환의 치료를 위한 융합된 비시클릭 화합물
CN104662006A (zh) 作为parp抑制剂的喹唑酮衍生物
JPH06145170A (ja) ヘテロ環式化合物、その製法及びこれを含有する高血圧及びうつ血性心不全治療用医薬組成物
AU2020256301A1 (en) Fused bicyclic compounds for the treatment of disease
WO2018211323A1 (en) Hetercyclic compounds for the treatment of disease
US20200071327A1 (en) Prodrugs for the Treatment of Disease
HK40070316A (en) Heterocyclic compounds for the treatment of disease
HK40070316B (en) Heterocyclic compounds for the treatment of disease
HK1260375B (en) Heterocyclic compounds for the treatment of disease
HK1260375A1 (en) Heterocyclic compounds for the treatment of disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000